E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neutropenic immunosuppressed |
|
E.1.1.1 | Medical condition in easily understood language |
Treatment of fungal infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate and compare caspofungin plasma concentration profiles and pharmacokinetic parameters (AUC0-24 hr, C1 hr, and C24 hr) obtained from 3- to 24-month-old children administered caspofungin, at 50 mg/m2/day (maximum of 70 mg/day) IV, to historical data from adult patients administered caspofungin at a daily 50-mg IV dose. |
|
E.2.2 | Secondary objectives of the trial |
(1) To compare caspofungin plasma concentration profiles and pharmacokinetics parameters (AUC0-24 hr, C1 hr, and C24 hr) obtained from 3- to 24-month-old children administered caspofungin, at 70 mg/m2/day (maximum of 70 mg/day) IV, to historical data from adult patients administered caspofungin at a daily 70-mg IV dose. (2) To evaluate the safety and tolerability of caspofungin administered as daily 50- and 70-mg/m2 IV doses in young children between the ages of 3 and 24 months. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• The patient is 3 to 24 months of age with one or more of the following conditions: 1) leukemia, lymphoma, or other cancers 2) bone marrow or peripheral stem transplantation 3) high dose chemotherapy incurring prolonged neutropenia 4) aplastic anemia • Patient has an absolute neutrophil count <500/mm3 (Note: The patient should have an anticipated duration of neutropenia of ≥10 days.) AND at least 1 recording of fever >38.0°C (oral or tympanic calibrated to oral) within 72 hours of screening.
|
|
E.4 | Principal exclusion criteria |
• Patient is <3 months or >24 months (2 years) of age (at time of drug administration). • Patient has proven or probable invasive fungal infection at the time of Enrollment • Patient is taking systemic antifungal therapy with the exception of prophylactic fluconazole.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate and compare caspofungin plasma concentration profiles and pharmacokinetic parameters (AUC0-24 hr, C1 hr, and C24 hr) obtained from 3- to 24-month-old children administered caspofungin, at 50 mg/m2/day |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Compare caspofungin plasma concentration profiles and pharmacokinetics parameters (AUC0-24 hr, C1 hr, and C24 hr) obtained from 3- to 24-month-old children administered caspofungin, at 70 mg/m2/day |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |